Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Gintant, G. A.
Right arrow Articles by Cox, B. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gintant, G. A.
Right arrow Articles by Cox, B. F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Utility of hERG Assays as Surrogate Markers of Delayed Cardiac Repolarization and QT Safety

Gary A. Gintant, Zhi Su, Ruth L. Martin and Bryan F. Cox

Deptartment of Integrative Pharmacology, Abbott Laboratories, Abbott Park, Illinois 60064-6119, USA

Correspondence: Address correspondence to: Gary Gintant, Dept. of Integrative Pharmacology (R46R, Bldg AP-9), Abbott Laboratories, 100 Abbott Park Rd., Abbott Park, IL 60064-6119, USA; e-mail:Gary.Gintant{at}abbott.com


   Abstract
TOP
 Abstract
Introduction
 Approaches to Evaluate Drug...
 Conclusion: hERG and Beyond
 References
 
HERG (human-ether-a-go-go-related gene) encodes for a cardiac potassium channel that plays a critical role in defining ventricular repolarization. Noncardiovascular drugs associated with a rare but potentially lethal ventricular arrhythmia (Torsades de Pointes) have been linked to delayed cardiac repolarization and block of hERG current. This brief overview will discuss the role of hERG current in cardiac electrophysiology, its involvement in drug-induced delayed repolarization, and approaches used to define drug effects on hERG current. In addition, examples of hERG blocking drugs acting differently (i.e., overt and covert hERG blockade due to multichannel block) together with the utility and limitations of hERG assays as tools to predict the risk of delayed repolarization and proarrhythmia are discussed.

Key Words: HERG • QT interval • Torsades de Pointes • arrhythmias • APD • repolarization

Abbreviations: APD, action potential duration • CHO, Chinese hamster ovary • EADs, early afterdepolarizations • ECG, electrocardiogram • HERG, human ether-a-go-go-related gene • HEK, human embryonic kidney • msec, milliseconds • QRS, QRS interval on the ECG • QT, QT interval on the ECG • TdP, Torsades de Pointes


   Introduction
TOP
 Abstract
 Introduction
Approaches to Evaluate Drug...
 Conclusion: hERG and Beyond
 References
 
Recent years have witnessed a heightened awareness regarding cardiovascular safety of drugs. In particular, a number of noncardiovascular drugs representing disparate chemical structures and therapeutic classes (including antihistamines, antibiotics, antifungals, antipsychotic, and gastrointestinal prokinetic agents) have been shown to delay ventricular repolarization. This effect has been linked to sudden cardiac death attributed to a rare, drug-induced polymorphic ventricular tachycardia termed Torsades de Pointes (TdP, Dessertennes, 1966) that may degenerate to ventricular fibrillation. In response to heightened awareness, actions from the pharmaceutical industry and regulatory agencies have included warnings, relabeling, and withdrawals from the marketplace. The reader is encouraged to read various articles reviewing the evolving scientific and regulatory perspectives (Haverkamp et al., 2000, Malik and Camm, 2001; Fermini and Fossa, 2003; Fenichel et al., 2004; Roden, 2004).

Drug-induced TdP occurs infrequently following administration of agents that alter or delay cardiac repolarization. Delayed repolarization is manifest as prolongation of the QT interval on the electrocardiogram. When properly controlled, QT prolongation may provide an antiarrhythmic property for therapeutic drugs specifically targeting the heart (see Shah and Hondeghem, 2005). However, drug-induced delayed repolarization with noncardiovascular drugs is generally considered as potentially harmful; such effects leading to QT interval prolongation have been termed acquired long QT syndrome. The rare occurrence of TdP and potentially lethal consequences necessitate the use of surrogate markers for this drug-induced event.

The most direct approach to evaluate drug-induced QT interval prolongation is to measure the interval (itself a surrogate marker). However, this approach has limitations related to the confounding effect of heart rate on the QT interval, the accurate measurement of the end of the interval, and the ability to reliably detect small changes in the QT interval (<5% of the interval) (Malik, 2002; Desai et al., 2003). In addition, while a link has been established between drug-induced QT prolongation and proarrhythmia (see later), the exact nature of that relationship is uncertain and likely varies with different drugs. Thus, additional surrogate markers are used to evaluate proarrhythmic risk related to altered ventricular repolarization; these include evaluation of drug effects on a cardiac repolarizing potassium current encoded by the hERG gene (termed hERG current studies), as well as studies that evaluate changes in the cardiac action potential configuration (termed action potential duration APD or repolarization studies). Congenital long QT syndromes, resulting from mutations in either cardiac potassium or sodium ion channel proteins or subunits, are also associated with QT prolongation, TdP, and sudden cardiac death (see Towbin and Vatta, 2001, Kass and Moss, 2003; Chiang, 2004 for reviews).

Ventricular repolarization is a dynamic electrophysiologic process that ensures the orderly termination of each heartbeat and modulates cardiac excitability and contractility. HERG is one of multiple cardiac ionic channels that provides repolarizing current and defines ventricular repolarization (Sanguinetti et al., 1995; Trudeau et al., 1995). Virtually all drugs that delay cardiac repolarization and cause TdP block the outward flow of repolarizing K+ current through hERG channels. Thus, hERG current block has become an accepted surrogate marker for cardiac proarrhythmia. This article reviews the role of hERG in ventricular repolarization and the utility of various hERG assays to predict altered repolarization and proarrhythmia. In addition, examples of hERG study results with clinically used drugs are provided to demonstrate the utility and weaknesses of the functional hERG current assay.

Primer on Ventricular Repolarization
The electrocardiogram (ECG) records the changing voltage on the body surface imparted by currents that flow throughout the heart. In general, the QT interval on ECG recordings represents the time from start of ventricular depolarization (Q-wave deflection) to end of ventricular repolarization (end of T-wave). As the time required for ventricular depolarization is short (typically < 60 msec in humans compared to 400 msec for the entire QT interval), the majority of the QT interval reflects ventricular repolarization. Thus, the QT interval is generally regarded as representing the duration of ventricular electrical activity, with QT prolongation predominantly reflecting delayed ventricular repolarization.

The cardiac action potential represents the characteristic configuration of transmembrane voltage (or potential) that occurs with each heartbeat (see Figure 1). This waveform represents the summation of multiple ion currents that turn on (activate) and off (deactivate or inactivate) with each beat. In the working ventricular myocardium, depolarization reflects the rapid activation of fast inward sodium current that depolarizes the membrane from the resting membrane potential to positive values to ensure rapid conduction; this current (analogous to sodium current in nervous tissue) is completed within a few milliseconds. On the ECG, the spread of ventricular depolarization is manifest as the spike-like QRS waveform. In contrast to depolarization, ventricular repolarization is much slower, taking a few hundred msec (much slower than nervous tissue) to bring the transmembrane potential back towards the resting potential. The slower time-course of repolarization is responsible for most of the approximately 400 msec QT interval duration.


Figure 10340081
View larger version (25K):
[in this window]
[in a new window]

  		Figure 1 Cardiac currents and channels that contribute to the ventricular action potential. The top trace illustrates a representative ventricular action potential. Successive horizontal traces represent various cardiac currents that are activated during the action potential. Downward deflections (representing inward depolarizing currents) are shown in upper panel; upward deflections (representing outward repolarizing currents) are shown below. During the action potential plateau, an inward (depolarizing) calcium current (ICa,L) diminishes, while an outward (repolarizing) delayed rectifier current IKr (encoded by hERG in humans) increases. Adopted from The Sicilian Gambit. A New Approach to the Classification of Antiarrhythmic Drugs Based on Their Actions on Arrhythmogenic Mechanisms. by the Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation 84, 1831–51.

 
Much of each ventricular action potential is spent during what is termed the "plateau" phase. During this time soon after the upstroke, a fine balance of declining inward (depo1arizing) current and increasing outward (repolarizing) currents is responsible for the relatively slow process of repolarization. As the plateau progresses, growing net outward current predominates, leading to terminal repolarization and the termination of the action potential (see Figure 1). Early during the plateau phase of the action potential, a depolarizing inward calcium current (carried through L-type calcium channels) is primarily responsible for sustaining membrane depolarization. Gradually, this current declines as a small but critical voltage-gated potassium current is activated, generating outward current, bringing the plateau to an end and initiating terminal repolarization (see Figures 1 and 2). This current has been termed IKr ("I" for current, "K" referring to potassium as the charge carrier, and ‘r" referring to the speed of current activation [specifically "r" for rapid, Sanguinetti and Jurkiewicz, 1990]). In humans, IKr flows through channels encoded by the human ether a-go-go-related gene hERG. Potent blocking drugs of IKr or hERG current (such as the specific blocking agent E-4031) have been used to delineate the contribution of this current during repolarization of the action potential.


Figure 20340081
View larger version (40K):
[in this window]
[in a new window]

  		Figure 2 Effect of block of IKr current on ventricular repolarization. Panel A illustrates 6 consecutive action potentials recorded from an isolated canine ventricular myocyte in the absence (Control) and presence of the potent hERG blocking drug E-4031. E-4031 prolongs the action potential duration without affecting other portions of the action potential. Panel B illustrates the E-4031 sensitive current (recorded from the same myocyte) that elicited the APD prolongation by drug block. The control action potential is illustrated by the smooth trace (left axis), while IKr (defined as that current blocked by E-4031) is illustrated by the noisier current recording (right axis). IKr steadily increases during the action potential plateau, reaching a peak amplitude near the end of the plateau to initiate terminal repolarization. [E-4031] = 5 µM. Stimulation rate 0.5 Hz. Perforated patch techniques were employed. From Gintant (2000).

 
HERG: What Is It?
HERG is an acronym for human ether-a-go-go-related gene, the gene that encodes the pore forming subunit of the delayed rectifier IKr channel in humans. The hERG channel is one of a family of ion channels first identified in a mutant Drosophila melanogaster fruitfly. In these fruitflies, exposure to ether anesthesia elicits leg shaking (hence the phrase "ether-a-go-go"). HERG was initially isolated by screening a human hippocampal cDNA library with a mouse homolog of ether-a-go-go, a Drosophila K+ channel gene. In humans, the gene resides at chromosone 7 q35-36; the channel is also known as KCNH2 (also referred to as Kv11.1). HERG was subsequently shown to be strongly expressed in heart (Curran et al., 1995), and to encode a K+ channel with properties similar to that of the rapidly activating delayed rectifier K+ current IKr (Sanguinetti et al., 1995; Trudeau et al.,1995).

An additional link between hERG and cardiac repolarization was provided by the finding of hERG mutations associated with a congenital long QT 2 syndrome linked to chromosome 7 (Curran et al., 1995). It is generally appreciated that most drugs that either delay repolarization or are associated with TdP block hERG current (see reviews cited above). Thus, block of hERG current has become an accepted surrogate marker for cardiac proarrhythmia and the evaluation of drug block of hERG current has come to play a pivotal role in the preclinical evaluation of potential proarrhythmic risk. In addition, a few drugs that delay repolarization may act by reducing the number of hERG channels in the plasma membrane to reduce hERG current density (Thomas et al., 2003; Ficker et al., 2004; Kuryshev et al., 2005).

The hERG channel is a K+ selective voltage-gated ion channel that activates upon depolarization and deactivates upon repolarization. Due to its inactivation properties, outward hERG current peaks later during cardiac repolarization (at less depolarized potentials, see Figure 2). Due to its unusual kinetic characteristics, hERG current also plays a unique role by providing current timed to suppress the initiation of premature beats (Smith et al., 1996; Spector et al., 1996; Lu et al., 2001). hERG current is monitored most readily using voltage clamp technique in which the transmembrane potential is experimentally controlled, and resulting ionic current flow across the membrane (the biological response) recorded (Figure 3). HERG current density in cardiac myocytes is small relative to many other currents, and thus difficult to measure in the presence of these larger time overlapping currents. However, hERG current is much more easily measured when it is the primary current (as when the pore forming subunit is expressed in heterologous systems such as HEK or CHO cells; Zhou et al., 1998). At least some drugs are thought to block hERG by binding to specific tyrosine and/or phenylalanine residues within the pore structure of the channel after gaining access from the intracellular space (Mitcheson et al., 2000; Milnes et al., 2003a; Witchel et al., 2004). HERG remains the only potassium channel target linked to delayed repolarization and a propensity towards proarrhythmia.


Figure 30340081
View larger version (26K):
[in this window]
[in a new window]

  		Figure 3 In vitro recordings of hERG current stably expressed in HEK-293 cells. Panel A: patch clamp electrode attached to cell stably transfected with hERG channels. The cell maintains a high intracellular K+ concentration compared to the extracellular solution. Panel B: Recording of voltage-dependent hERG current activated upon depolarization, and deactivated upon repolarization. The declining outward current upon repolarization is termed the tail current. Panel C: Recordings of hERG current under control conditions (upper most trace), and during exposure to increasing concentrations of a hERG blocking drug. Tail currents demonstrate a concentration-dependent reduction. Panel D:IC50 values characterizing potency of hERG current block derived from Hill equation fit to experimental data.

 

   Approaches to Evaluate Drug Effects on HERG
TOP
 Abstract
 Introduction
 Approaches to Evaluate Drug...
Conclusion: hERG and Beyond
 References
 
Indirect Techniques To Monitor hERG Current
Various approaches have been developed to evaluate drug effects on hERG current. These can be conveniently divided into two categories based on whether direct or indirect measures of hERG current are made. Indirect approaches include binding assays, assays measuring ionic flux changes, and those detecting changes in membrane potential. Binding assays that measure displacement of potent, radiolabeled hERG ligands by drugs provide a convenient screening method to detect drug-hERG channel interactions. Such systems may conveniently use intact cells or cell membranes from heterologous expression systems transfected with the hERG channel and potent, radiolabeled hERG ligands such as dofetilide (Diaz et al., 2004). Similar studies have utilized displacement of other hERG channel ligands, including the methanesulfonanilide MK-499 (Wang et al., 2003) and astemizole (Chiu et al., 2004).

Another indirect approach employed to detect hERG channel-drug interactions is the ion flux assay. This assay measures reduced levels of radiolabeled Rb+ efflux (reflecting diminished outward K+ current through hERG channels) from hERG-transfected cells (Rezazadeh et al., 2004). Voltage-sensitive dyes have also been used to measure drug-induced membrane depolarization of hERG transfected cells in which hERG/IKr is the primary potassium current responsible for setting the resting membrane potential (Netzer et al., 2003). Results obtained with these indirect assays are less sensitive than those reported using direct measures of hERG current. The primary advantage of these indirect approaches is greater throughput achieved compared with assays that directly measure changes in hERG current. New approaches using planar patch techniques coupled to automation provide direct measures of hERG current and are poised to challenge the use of indirect techniques (Dubin et al., 2005, Guo and Guthrie, 2005). However, the ability of these automated systems to match the throughput of indirect screening assays remains to be proven.

The characterization of changes in hERG current measured directly remains the "gold standard" for evaluating drug effects. Figure 3 illustrates hERG current recorded from a HEK cell stably transfected with the hERG channel; under these experimental conditions, hERG is the predominant current (recorded without interfering contaminating currents). As hERG is a voltage-gated channel, it is activated and deactivated by changes in the transmembrane potential (see Figure 3B). Using voltage clamp techniques, the voltage is controlled ("clamped") by the investigator, and transmembrane current that flows in response to the changes in the channel conformation is monitored. When this approach is applied to cells transfected with the hERG channel, increasing outward current is recorded upon membrane depolarization (representing current activation). Upon repolarization, a decreasing outward hERG current (termed hERG tail current) is recorded, representing channel deactivation. The amplitude of the tail currents recorded in the absence and presence of drugs can be compared to determine the IC50 values for hERG current block (that is, the concentration of drug required to block 50% of hERG current, see Figure 3C and 3D). Concentration-response curves are constructed to determine IC50 values for hERG current block.

General Limitations of Evaluations of HERG Channel Block
IC50 values characterizing drug block of hERG current provide a convenient way to compare the potency of drugs. However, it should be recognized that IC50 values for hERG block represent a simplification of potentially complex time-, voltage-, and state-dependent block and unblock of hERG current. Some drugs (such as dofetilide [Snyders and Chaudhary, 1996; Weerapura et al., 2002] and mesoridazine [Su et al., 2004]) are referred to as "open channel blockers," because channel activation is required to reduce hERG current. It has been proposed that compounds may block open channels by binding to different sites within the channel cavity; the lower-affinity hERG blocker propafenone behaves as an "open state blocker" but does not appear to interact with the aromatic residue Tyr652 as do some higher affinity hERG blocking methanesulfonanilides (Witchel et al., 2004). A few drugs may block hERG exclusively by interacting with closed channels (fluvoxamine (Milnes, 2003a); peptide toxins have been shown to act preferentially in this manner (Milnes et al., 2003b). Thus, the configuration (and frequency of repetition) of the voltage clamp waveform may affect the potency of block as well as the time course of block and recovery, reflecting interactions with different states of the channel (see Tsujimae et al., 2004 for a comparison of quinidine and dofetilide block of hERG current).

It should also be noted that the choice of experimental preparation and conditions also affects determinations of the potency of hERG block. Studies measuring hERG current in oocytes injected with hERG mRNA typically report IC50 values less potent than those obtained using either HEK or CHO cells transfected with hERG. This effect is likely due to the yolk sac in oocytes acting as a drug "reservoir" (Witchel et al., 2002a). Temperature has been shown to affect IC50 value determinations for some compounds; a recent study by Kirsch et al. (2004) demonstrated that increasing the temperature from 22 to 35° C elicited a statistically significant decreased blocking potency for 2 drugs, increased potency for 4 drugs, and had no effect on 9 additional drugs evaluated using a 2-second step pulse clamp protocol; for the same change in temperature, Yao and colleagues also reported an increased potency for hERG block with 1 drug, decreased potency for a second drug, and no changes in 2 additional drugs (Yao et al., 2005).

Finally, attention must be paid to measuring bath concentrations of tested compounds, as drug levels may be lower than targeted due to degradation and adsorption to perfusion tubing (unpublished observations see also data cited in Brown, 2004). Such differences in protocols and techniques contribute to the range of IC50 values for compounds reported in the growing hERG pharmacologic literature (see for example Figure 4, also Kirsch et al., 2004), and demonstrate the necessity of routinely including an accepted and widely used positive control standard to monitor the assay sensitivity.


Figure 40340081
View larger version (54K):
[in this window]
[in a new window]

  		Figure 4 A comparison of therapeutic drug concentration ranges (total plasma concentrations lightly hashed rectangles) and calculated free plasma concentrations darker hashed rectangles vs. IC50 values for hERG block (upward triangles) and calcium current block (ICa,L, downward open triangles). Drugs associated with QT prolongation and/or Torsades-de-Pointes (dofetilide, cisapride, and terfenadine, examples of overt hERG blocking drugs) have IC50 values for hERG block overlapping drug exposures. In contrast, in cases where where calcium current block may be present, a link with proarrhythmia is absent (fluoxetine, verapamil). In such cases, multichannel block may provide the mechanism for covert hERG blocking drugs. IC50 values for hERG block chosen from literature using either transfected HEK or CHO cells, native ventricular myocytes or atrial tumor cells (References used for drug concentrations displayed in figure 4 are listed by italicized drug abbreviations at the end of each reference. Cisa. = cisapride; Dofet. = dofetilide; Fluox. = fluoxetine; Terf. = terfenadine;Verap. = verapamil). Rightward arrows indicate IC50 values greater than symbol placement. Plasma protein binding values used to calculate free drug concentrations were 65%, 98%, 97%, 94%, and 90% for dofetilide, cisapride, terfenadine, fluoxetine, and verapamil, respectively. Met. Mult = metabolic multiplication. See text for further discussion.

 
IC50 values for hERG block (obtained in the absence of plasma proteins) are compared to plasma drug concentrations to gain insight into safety margins for proarrhythmic risk (see next). However, the free concentration of drugs extensively bound to plasma proteins may be significantly lower than total drug concentration. Controversy exists regarding how to correct for the potential effects of plasma protein binding. For a series of 5 antipsychotic drugs (with plasma protein binding ranging from 83–99%), the safety margin for hERG block (assessed as the ratio of hERG IC50 values to total plasma concentrations) corresponded well with QT prolongation clinically; free (unbound) drug plasma levels did not provide as reliable a correlation (Kongsamut, 2002). In contrast, the ratio of hERG IC50 values to free plasma concentrations was predictive of QT prolongation for a series of seven fluoroquinolone antibiotics (weak plasma protein binding ranging from 20–50%, Kang et al., 2001). Given such discrepancies, it is recommended that total and (calculated) free drug plasma concentrations both be considered when reviewing safety margins in relation to hERG block.

Evaluation of Proarrhythmic Risk Based on hERG Current: hERG block in Context
While a general relationship between hERG blockade and proarrhythmic risk for most noncardiovascular drugs (as well as some cardiovascular drugs) is generally accepted, the characteristics of that relationship remains uncertain. Trends have been noted relating hERG block with the clinical QT prolongation and TdP. Redfern and colleagues (2003) summarized published in vitro electrophysiologic data from 52 compounds, comparing potency of hERG (or IKr) current block with clinical experience related to QT interval prolongation and reports of TdP in humans; these data were set against free plasma concentrations during clinical use (effective therapeutic plasma concentrations [ETPC unbound]).

For these comparisons, drugs were categorized into 5 groups based upon clinical experience, with higher numbers associated with reduced proarrhythmic risk: (1) Antiarrhythmic drugs expected to prolong cardiac repolarization); (2) Drugs withdrawn from the market due to TdP; (3) Drugs with measurable incidence/numerous TdP reports, (4) Drugs with isolated reports of TdP in humans; (5) No reports of TdP in humans. Drugs within each category were then characterized based on the ratio of their lowest reported hERG IC50 values vs. calculated unbound Cmax values, defining a "safety margin." The dataset demonstrated that most drugs associated with TdP have IC50 values close to or superimposed upon free drug plasma concentrations found in clinical use. While a 30-fold margin between Cmax and hERG IC50 values was generally predictive of cardiac safety, the authors noted that increasing this margin should be considered to ensure cardiac safety, especially for future drugs aimed at nondebilitating diseases.

A closer evaluation of the dataset analyzed by Redfern and colleagues reveals that some drugs not associated with TdP in humans (categories 4 and 5) are characterized with hERG IC50 values comparable to calculated free plasma concentrations (e.g., verapamil). We use the term "overt hERG blocker" to classify drugs that either delay repolarization in integrated systems (APD repolarization or QT assays) or are linked to TdP at unbound (free) concentrations comparable to those that block hERG. These drugs elicit hERG block and QT prolongation over comparable concentration ranges. In contrast, we use the term "covert hERG blocker" to describe drugs that do not delay repolarization in integrated systems or elicit TdP but block hERG current at comparable unbound (free) concentrations. A comparison of select drugs representing overt and covert hERG blocking agents is instructive in defining the utility and limitations of the hERG functional current assay as a surrogate marker of proarrhythmic risk.

Dofetilide: An Example of an "Overt" hERG Blocking Drug
Dofetilide is a highly potent and specific blocker of IKr (hERG) current used to treat atrial fibrillation by blocking IKr in human atria. However, dofetilide also blocks IKr present in the ventricle. IC50 values for current block in the literature are in the low nanomolar range, and not far from plasma concentrations (see Figure 4). Dofetilide elicits concentration-dependent prolongation of the QTc interval at total plasma concentrations as low as 3.4 nM (Tikosyn product monograph) and is an example of an overt hERG blocking drug.

Cisapride and Terfenadine: Examples of Overt hERG Blocking Drugs Resulting from "Metabolic Multiplication"
Cisapride
Cisapride is a gastrointestinal prokinetic agent formerly used widely for the treatment of gastroesophageal reflux disease (GERD). First marketed in 1981, and ranked 73rd most dispensed drug in the United States in 1996 with over 5.4 million prescriptions filled, this drug was withdrawn from the market in 1997. Cardiotoxicity with cisapride is associated with high doses, or with concomitant use of drugs that inhibit the cytochrome P-450 3A4 enzyme system responsible for cisapride metabolism, leading to excessive plasma concentrations of the drug (Ahmad and Wolf, 1995, Pettignano et al., 1996). Increasing (and excessive) plasma concentrations of drugs arising after metabolic inhibition has been referred to as "metabolic multiplication."

Figure 4 illustrates the therapeutic total plasma concentrations of cisapride, along with calculated free concentrations and reported IC50 values for hERG block. Cisapride can be considered an overt hERG blocking drug as supratherapeutic plasma levels that approach or exceed concentrations eliciting hERG block are associated with delayed repolarization and TdP.

Terfenadine
Terfenadine was one of the first non-cardiovascular drugs linked to TdP clinically and shown to prolong the QT interval. Initially marketed in 1981, terfenadine ranked 9th in total prescriptions dispensed in 1991, eventually being withdrawn from the market in 1997. Lessons learned with this drug highlight the potential risks resulting from metabolic multiplication. In most instances, terfenadine is rapidly and almost completely metabolized following oral administration by cytochrome P450 (CYP) 3A4 oxidases to an active compound essentially devoid of hERG blocking effects (fexofenadine).

However, in cases of inhibition of the CYP 3A4 oxidases (for example, with concomitant administration of ketoconazole), excessive concentrations of the parent compound terfenadine can result (see Figure 4), leading to concentration-dependent prolongation of the QT interval (Honig et al., 1993). Terfenadine was shown to block IKr in feline ventricular myocytes (Woosley, 1993); a link to the hERG channel as the molecular target was later demonstrated (Roy et al., 1996). Similar exacerbations of untoward drug effects have been reported with other hERG blocking drugs such as astemizole and cisapride (see review by Dresser, 2000). Terfenadine is an example of an overt hERG blocking drug in that supratherapeutic plasma concentrations attained after metabolic multiplication are comparable to IC50 values for hERG block and may elicit delayed repolarization and QT prolongation. These findings highlight the importance of relating hERG block to targeted therapeutic concentration and excessive plasma concentrations that may arise from adverse pharmacokinetic interactions.

Verapamil and Fluoxetine: Covert hERG Block Arising from Multichannel Block
The term "multi-channel block" refers to the reduction of other (non-HERG) cardiac currents by hERG-blocking drugs. Given the multiple ion channels, pumps, and exchanges that contribute to the cardiac action potential, it is likely that some drugs reduce additional cardiac currents other than hERG. As a result, these drugs may produce electrophysiologic effects distinctly different from drugs solely affecting hERG block, providing an ionic mechanism to explain covert hERG blockade. In vitro, delayed repolarization elicited by hERG block can be attenuated by reduction of either the L-type calcium current or late cardiac sodium current (see Martin et al., 2004); the former case is consistent with the electrophysiological effects of verapamil and fluoxetine, two covert hERG blockers.

Verapamil
Verapamil is an L-type calcium channel blocker with vasodilatory and antiarrhythmic actions first marketed in 1981 and used to treat angina pectoris, arrhythmias, and hypertension. In in vitro action potential studies, verapamil reduces the height of the action potential plateau and accelerates repolarization during the action potential plateau, both consistent with block of calcium current (Rosen et al., 1974). The use of this calcium channel blocking drug is not associated with either QT prolongation or risk of TdP. However, verapamil has been demonstrated to be a potent hERG blocker, with IC50 values for hERG block ranging from 0.094 to 3 µM; these values overlap therapeutic exposures (0.1–0.8 µM [total concentrations] and 0.01–0.08 µM [calculated free plasma concentrations], see Figure 4). A reported IC50 value for block of L-type calcium current block (0.164 µM) is also near values cited for hERG block.

The lack of association between hERG block and either QT prolongation or TdP with verapamil is consistent with the concomitant reduction of cardiac L-type calcium current mitigating the effects of hERG block. In general, reduction of calcium current (an inward depolarizing current during the action potential plateau) leads to a reduction in the height of the plateau and minimal effects (or abbreviation) of the action potential duration. Thus, a drug that reduces inward (depolarizing) calcium current could "balance" the diminished outward repolarizing current (resulting from hERG block) to minimize repolarization delays (and proarrhythmia). In in vitro studies with Purkinje fibers, delayed repolarization elicited by the specific IKr blocking drug dofetilide was significantly alleviated by the concomitant administration of the selective calcium channel blocking agent nifedipine (see Figure 5). Indeed, combined potassium and calcium channel blocking properties have been proposed as the basis for the lower proarrhythmic risk of the experimental antiarrhythmic compound BRL-32872 (Bril et al., 1996), especially at high concentrations shown to elicit less APD prolongation compared to lower concentrations. Thus, calcium channel block can attenuate the APD prolonging effects of hERG block.


Figure 50340081
View larger version (38K):
[in this window]
[in a new window]

  		Figure 5 Effects of "Multi-channel block" on cardiac repolarization. Panels A and B. Effect of concurrent block of cardiac calcium current ICa,L. Panel A illustrates action potentials recorded from a canine cardiac Purkinje fiber recorded sequentially under drug-free conditions (Control), in the presence of the IKr (hERG) channel blocker dofetilide (Dofetilide), and during exposure to the calcium channel blocker nifedipine in the continued presence of dofetilide (Dofetilide + Nifedipine). APD prolongation elicited by dofetilide is significantly reduced by nifedipine. Panel B illustrates summarized results. Panels C and D: Effect of concurrent block of cardiac sodium current. Panel C illustrates actions potentials recorded from a fiber under drug-free conditions (Control), in the presence of IKr block with dofetilide, and during exposure to the sodium channel blocker lidocaine in the continued presence of dofetilide (Dofetilide + Lidocaine). APD prolongation elicited by dofetilide was reversed by the addition of 25 µM lidocaine. Panel D summarizes concentration-dependent reversal of dofetilide-induced delayed repolarization by lidocaine. Stimulation rate 2 sec BCL; dofetilide conc = 0.1 µM; nifedipine concentration = 5 µM; lidocaine concentrations of 5 and 25 µM. From Martin et al. (2004).

 
Block of calcium current may also reduce proarrhythmic risk of hERG blockade by preventing the initiation of early afterdepolarizations (EAD’s) during prolonged action potentials. EAD’s are aberrant depolarizing "spikes" that arise from the plateau phase of prolonged action potentials (Fozzard, 1992); this triggered activity can propagate into surrounding tissue and may be responsible for initiating TdP (Yan et al., 2001). Drugs that reduce L-type calcium channel block may prevent TdP by preventing the EAD’s likely responsible for initiating this arrhythmia (January 1991).

Fluoxetine
Fluoxetine is an antidepressant drug first marketed in 1986 with extensive clinical experience (worldwide exposure estimated to be more than 38 million patients circa, 1999) that is not usually associated with either QT prolongation or TdP. Fluoxetine has also been reported to block hERG current (IC50 values ranging from 0.46 to 1.5 µM). Tese concentrations approximate the total therapeutic plasma concentrations (0.3–2.6 uM, Figure 4E). In addition, fluoxetine has also been demonstrated to block L-type calcium current at slightly higher concentrations (IC50 values of 2.8 and 5.4 uM, see Figure 4). Fluoxetine’s lack of association with either delayed repolarization or TdP is consistent with multichannel block; indeed, supratherapeutic fluoxetine concentrations (approximately 60 µM, well above the IC50 value for hERG block) actually shorten the canine cardiac Purkinje fiber action potential duration in vitro (Gintant et al., 2001). In the present regulatory environment, it has been argued that a drug with a hERG profile similar to the widely used antidepressant fluoxetine might either not be developed today and would be subject to special (and likely unnecessary) use restrictions (Fermini and Fossa, 2003).

HERG Block: One of Multiple Risk Factors for Proarrhythmia
Finally, it is generally accepted that TdP arises as a result of the unfortunate coincidence of multiple risk factors manifest at one time (Roden, 1998). A retrospective review of reports of drug-induced TdP from 249 patients with noncardiac drugs found at least one easily identified risk factor, with 71% of patients having 2 or more risk factors (Zeltser et al., 2003). The most prevalent risk factors were female gender, heart disease, hypokalemia, pharmacodynamic drug interactions (use of multiple drugs that affect repolarization), and pharmacokinetic interactions (potential interference with the metabolism of a QT-prolonging drug by a second medication). The presence of congenital mutations of cardiac ion channels may also play a role in increasing the risk of drug-induced TdP (Roden, 2004). All of these factors may reduce the ability of the ventricle to repolarize by reducing net outward current (referred to as "repolarization reserve," Roden, 1998), rendering the heart more susceptible to delayed repolarization and potential proarrhythmia by hERG blocking drugs. The above observations dictate that the relative potency of hERG block represents only one of multiple factors that need to be considered when evaluating proarrhythmic risk. Thus, an evaluation of potential proarrhythmic effects of drugs based on hERG current block alone provides an incomplete view of a drug’s potential to affect the complex and integrated process of cardiac repolarization in vitro and in vivo.


   Conclusion: hERG and Beyond
TOP
 Abstract
 Introduction
 Approaches to Evaluate Drug...
 Conclusion: hERG and Beyond
References
 
Torsades de Pointes is a rare arrhythmia that usually results from a simultaneous convergence of risk factors that lead to significant impaired or delayed cardiac repolarization. Drugs that block hERG, a critical cardiac repolarizing current involved in initiating terminal cardiac repolarization, act to prolong ventricular repolarization and have been linked with TdP. HERG is the only molecular potassium channel target linked to delayed repolarization and a propensity towards proarrhythmia. Thus, block of hERG current has become an accepted surrogate marker for TdP.

The potential proarrhythmic risk associated with hERG current block must first be considered in the context of potency of hERG block in relation to therapeutic plasma concentrations. Other factors that must be considered when assessing a drug’s potential proarrhythmia include: pharmacokinetic interactions (the potential for accentuated block due to excessive drug concentrations resulting from drug-drug interactions [e.g. metabolic multiplication], pharmacodynamic interactions (multiple drugs simultaneously reducing hERG current), and a changing electrophysiologic substrate (e.g., cardiac disease, hypokalemia). In the case of overt hERG blockers, drug effects are manifest predictably as concentration-dependent QT prolongation (and presumably greater risk for TdP) as drug concentrations approximate IC50 values for hERG block. In contrast, covert hERG blockers may not delay repolarization as a result of concomitant block of other (non-hERG) cardiac currents (e.g., L-type calcium current, late sodium current [multichannel block]) mitigating hERG block when therapeutic concentrations approximate IC50 values.

Finally, additional systemic (non-cardiac) "off-target" drug effects may further modulate hERG blockade (for example, drugs modulating autonomic influences to indirectly affect cardiac repolarization; see Fossa et al., 2005). Thus, hERG current block represents only one important part of a multifactorial integrated risk assessment that must include subcellular (hERG current assays), cellular (in vitro APD-repolarization assays) and in vivo (ECG-QT) components providing a balanced evaluation of proarrhythmic risk. Newer in vitro models are needed to quantitatively characterize the relationship between hERG block and proarrhythmic potential, especially for covert hERG blocking compounds.


   References
TOP
 Abstract
 Introduction
 Approaches to Evaluate Drug...
 Conclusion: hERG and Beyond
 References
 

  • Ahmad, SR, & Wolfe, SM. (1995). Cisapride and Torsades de pointes. Lancet, 345, 508
  • Bril, A, Gout, B, Bonhomme, M, Landais, L, Faivre, JF, Linee, P, Poyser, RH, & Ruffolo, RR., Jr. (1996). Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL32872. J Pharm Exp Ther, 276(2), 637-46[Abstract/Free Full Text]
  • Brown, AM. (2004). Drugs, hERG and sudden death. Cell Calcium, 35(6), 543-7[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Brunswick, DJ, Amsterdam, JD, Fawcett, J, Quitkin, FM, Reimherr, FW, Rosenbaum, JF, & Beasley, CM., Jr. (2002). Fluoxetine and norfluox-etine plasma concentrations during relapse-prevention treatment. J Affect Disord, 68(2–3), 243-9. Fluox. Fluox. Fluox.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Carmeliet, EE. (1992). Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide. J Pharmacol Experim Ther, 262(2), 809-17. Dofet. Dofet. Dofet.
  • Chiang, CE. (2004). Congenital and acquired long QT syndrome. Current concepts and management. Cardiol Rev, 12(4), 222-34[CrossRef][Medline] [Order article via Infotrieve]
  • Chiang, CE, Wang, TM, & Luk, HN. (2004). Inhibition of L-type Ca++ current in Guinea pig ventricular myocytes by cisapride. J Biomed Sci, 11(3), 303-14. Cisa. Cisa. Cisa.[Web of Science][Medline] [Order article via Infotrieve]
  • Chiu, PJS, Marcoe, KF, Bounds, SE, Lin, C-H, Feng, J-J, Lin, A, Cheng, F-C, Crumb, WJ, & Mitchell, R. (2004). Validation of a [3H] Astemizole Binding assay in HEK293 cells expressing HERG K+channels. J Pharmacol Sci, 95, 311-9[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Chouabe, C, Drici, MD, Romey, G, Barhanin, J, & Lazdunski, M. (1998). HERG and KvLQT1/IsK, the cardiac K + channels involved in long QT syndromes, are targets for calcium channel blockers. Mol Pharmacol, 54(4), 695-703. Verap. Verap. Verap.[Abstract/Free Full Text]
  • Curran, ME, Splawski, I, Timothy, KW, Vincent, GM, Green, ED, & Keating, MT. (1995). A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell, 80(5), 795-803[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Davie, C, Pierre-Valentin, J, Pollard, C, Standen, N, Mitcheson, J, Alexander, P, & Thong, B. (2004). Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (IKr) channel. J Cardiovasc Electrophysiol, 15(11), 1302-9. Cisa, Dofet, Verap. Cisa, Dofet, Verap. Cisa, Dofet, Verap.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Davies, AJ, Harindra, V, McEwan, A, & Ghose, RR. (1989). Cardiotoxic effect with convulsions in terfenadine over dose. Br Med J, 298, 325, Terf. Terf. Terf.[Free Full Text]
  • Desai, M, Li, L, Desta, Z, Malik, M, & Flockhart, D. (2003). Variability of heart rate correction methods for the QT interval. Br J Clin Pharmacol, 55(6), 511-7[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Dessertenne, F. (1966). La tachycardia ventriculaire a deux foyers opposes variables. Arch Mal Coeur, 59, 263-72[Medline] [Order article via Infotrieve]
  • Diaz, G, Daniell, K, Lietza, ST, Martin, RL, Su, Z, McDermott, JS, Cox, BF, & Gintant, GA. (2004). The [3H] dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o. J Pharmacol Toxicol Meth, 50(3), 187-99[CrossRef][Medline] [Order article via Infotrieve]
  • Dresser, GK, Spence, JD, & Bailey, DG. (2000). Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet, 38(1), 41-57[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Drolet, B, Khalifa, M, Daleau, P, Hamelin, BA, & Turgeon, J. (1998). Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation, 97(2), 204-10. Cisa. Cisa. Cisa.[Abstract/Free Full Text]
  • DRUGDEX® System, Klasco, RK (Ed.). DRUGDEX® System. Greenwood Village Colorado (Edition expires 2006): Thomson Mi-cromedex
  • Dubin, AE, Nasser, N, Rohrbacher, J, Hermans, AN, Marrannes, R, Grantham, C, Van Rossem, K, Cik, M, Chaplan, SR, Gallacher, D, Xu, J, Guia, A, Byrne, NG, & Mathes, C. (2005). Identifying modulators of hERG channel activity using the PatchXpress PlanarPatch Clamp. J Biomolec Screen, 10(2), 168-81
  • Fermini, B, & Fossa, AA. (2003). The impact of drug-induced QT interval prolongation on drug discovery and development. Nature Rev Drug Disco V, 2, 439-47[CrossRef]
  • Fenichel, RR, Malik, M, Antzelevitch, C, Sanguinetti, M, Roden, DM, Priori, SG, Ruskin, JN, Lipicky, RJ, & Cantilena, LR. (2004). Drug induced Torsades-de-Pointes and implications for drug development. J Cardiovasc Electrophys, 15(4), 475-95[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ficker, E, Kuryshev, YA, Dennis, AT, Obejero-Paz, C, Wang, L, Hawryluk, P, Wible, BA, & Brown, AM. (2004). Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol, 66(1), 33-44[Abstract/Free Full Text]
  • Fossa, AA, Wisialowski, T, Wolfgang, E, Wang, E, Avery, M, Raunig, DL, & Fermini, B. (2004). Differential effect of hERG blocking agents on cardiac electrical alternans in the guinea pig. Eur J Pharmacol, 486, 209-21. Cisa, Verap. Cisa, Verap. Cisa, Verap.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fossa, AA, Wisialowski, T, Mangano, A, Wolfgang, E, Winslow, R, Gorczyca, W, Crimin, K, & Raunig, DL. (2005). Dynamic beat-to-beat modeling of th QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go related gene inhibition. J Pharmacol Exp Ther, 312(1), 1-11[Abstract/Free Full Text]
  • Fozzard, HA. (1992). Afterdepolarizations and triggered activity. Basic Res Cardiol, 87 (Suppl_2), 105-13[Web of Science][Medline] [Order article via Infotrieve]
  • Gintant, GA. (2000). Characterization and functional consequences of delayed rectifier current transient in ventricular repolarization. Am J Physiol (Heart Circ Physiol), 278, H806-17[Abstract/Free Full Text]
  • Gintant, GA, Limberis, JT, McDermott, JS, Wegner, CD, & Cox, BF. (2001). The Canine Purkinje fiber: An in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Car-diovasc Pharm, 37, 607-18[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gladziwa, U, Bares, R, Klotz, U, Dakshinamurty, KV, Ittel, TH, Seiler, K-U, & Sieberth, H-G. (1991). Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis. Clin Pharmacol Ther, 50, 673-81. Cisa. Cisa. Cisa.[Web of Science][Medline] [Order article via Infotrieve]
  • Guo, L, & Guthrie, H. (2005). Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. J Pharmacol Tox Methods, 52(1), 123-35[CrossRef][Medline] [Order article via Infotrieve]
  • Haverkamp, W, Breithardt, G, Camm, AJ, Janse, MJ, Rosen, MR, Antzelevitch, C, Escande, D, Franz, M, Malik, M, Moss, A, & Shah, R. (2000). The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovascular Res, 47, 219-33[Free Full Text]
  • Honig, PK, Worthan, DC, Zamani, K, Conner, DP, Mullin, JC, & Cantilena, LR. (1993). Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA, 269(12), 1550-2[Abstract/Free Full Text]
  • January, CT, Chau, V, & Makielski, JC. (1991). Triggered activity in the heart: cellular mechanisms of early after-depolarizations. Eur Heart J, 12(suppl F), 4-9[Abstract/Free Full Text]
  • Jones, SE, Missan, S, Zhabyeyev, P, & McDonald, TF. (2000). Selective phenylalkylamine block of IKr over other K+ currents in guinea-pig ventricular myocytes. Br J Pharmacol, 131, 1809-16. Verap. Verap. Verap.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Jurkiewicz, NK, & Sanguinetti, MC. (1993). Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide Class III antiar-rhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circ Res, 72, 75-83. Dofet. Dofet. Dofet.[Abstract/Free Full Text]
  • Kang, J, Wang, L, Chen, XL, Triggle, DJ, & Rampe, D. (2001). Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol, 59(1), 122-6[Abstract/Free Full Text]
  • Kass, RS, & Moss, AJ. (2003). Long QT syndrome: novel insights into the mechanisms of cardiac arrhythmias. J Clin Invest, 112(6), 810-5[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kirsch, GE, Trepakova, ES, Brimecombe, JC, Sidach, SS, Erickson, HD, Kochan, MC, Shyjka, LM, Lacerda, AE, & Brown, AM. (2004). Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J Pharmacol Toxicol Meth, 50(2), 93-101. Cisa, Fluox, Terf, Verap. Cisa, Fluox, Terf, Verap. Cisa, Fluox, Terf, Verap.[CrossRef][Medline] [Order article via Infotrieve]
  • Kongsamut, S, Kang, J, Chen, XL, Roehr, J, & Rampe, D. (2002). A comparison of the receptor binding of HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol, 450(1), 37-41[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kuryshev, YA, Ficker, E, Wang, L, Hawryluk, P, Dennis, AT, Wible, BA, Brown, AM, Kang, J, Chen, XL, Sawamura, K, Reynolds, W, & Rampe, D. (2005). Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther, 312(1), 316-23[Abstract/Free Full Text]
  • Lacy, CF, Armstrong, L, Goldman, MP, & Gance, LL. (1999). Drug Information Handbook. Am Pharm Ass’n. (Fluox). (7). Ohio, USA: Hudson. 1999–2000.
  • Liu, S, Melchert, RB, & Kennedy, RH. (1997). Inhibition of L-type Ca2+ channel current in rat ventricular myocytes by terfenadine. Circ Res. 81(2), 202-10. Terf. Terf. Terf.[Abstract/Free Full Text]
  • Lu, Y, Mahaut-Smith, MP, Varghese, A, Huang, CL, Kemp, PR, & Vandenberg, JL. (2001). Effects of premature stimulationon HERG K+ Channels. J Physiol. 537(Pt 3), 843-51[Abstract/Free Full Text]
  • Malik, M. (2002). The imprecision in heart rate correction may lead to artificial observations of drug induced QT interval changes. Pacing Clin Electro-physiol, 25(2), 209-16[CrossRef][Medline] [Order article via Infotrieve]
  • Malik, M, & Camm, AJ. (2001). Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf, 24(5), 323-51[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Martin, RL, McDermott, JS, Salmen, HJ, Palmatier, J, Cox, BF, & Gintant, GA. (2004). The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: Influence of Multi-Channel Block. J Cardiovasc Pharm , 43(3), 369-79. Cisa. Fluox. Terf. Cisa. Fluox. Terf. Cisa. Fluox. Terf.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Milnes, JT, Crociani, O, Arcangeli, A, Hancox, JC, & Witchel, HJ. (2003a). Blockade of hERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol, 139(5), 887-98[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Milnes, JT, Dempsey, CE, Ridley, JM, Crociani, O, Arcangeli, A, Hancox, JC, & Witchel, HJ. (2003b). Perferential closed channel blockade of HERG potassium currents by chemically synthesized BeKm-1 scorpion toxin. FEBS Lett, 547, 20-6[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ming, Z, & Nordin, C. (1995). Terfenadine blocks time-dependent Ca2+, Na+ and K+ channels in guinea pig ventricular myocytes. J Cardiovasc Pharmacol, 26(5), 761-9. Terf. Terf. Terf.[Web of Science][Medline] [Order article via Infotrieve]
  • Mitcheson, JS, Chen, J, Lin, M, Culberson, C, & Sanguinetti, MC. (2000). A structural basis for drug-induced long QT syndrome. PNAS, 97(22), 12329-33[Abstract/Free Full Text]
  • Monahan, BP, Ferguson, CL, Killeavy, ES, Lloyd, BK, Troy, J, & Cantilena, LR. (1990). Torsades de pointes occurring in association with terfenadine use. J Amer Med Assoc, 264, 2788-90. Terf. Terf. Terf.[Abstract/Free Full Text]
  • Nawrath, H, Klein, G, Rupp, J, Wegener, JW, & Shainberg, A. (1998). Open state block by fendiline of L-type Ca++ channels in ventricular myocytes from rat heart. J Pharmacol Exp Ther, 285(2), 546-52. Verap. Verap. Verap.[Abstract/Free Full Text]
  • Netzer, R, Bischoff, U, & Ebneth, A. (2003). HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery. Curr Opin Drug Discov Devel, 6(4), 462-9[Web of Science][Medline] [Order article via Infotrieve]
  • Pacher, P, Magyar, J, Szigligeti, P, Banyasz, T, Pankucsi, C, Korom, Z, Ungvari, Z, Kecskemeti, V, & Nanasi, PP. (2000). Electrophysiological effects of fluoxetine in mammalian cardiac tissues. Naunyn Schmiedebergs Arch Pharmacol, 361(1), 67-73. Fluox. Fluox. Fluox.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Park, KS, Kong, ID, Park, KC, & Lee, JW. (1999). Fluoxetine inhibits L-type Ca2 + and transient outward K + currents in rat ventricular myocytes. Yonsei Med J, 40(2), 144-51. Fluox. Fluox. Fluox.[Web of Science][Medline] [Order article via Infotrieve]
  • Paul, AA, Leishman, DJ, Witchel, HJ, & Hancox, JC. (2001). Effects of the class III antiarrhythmic agent dofetilide (UK-68,798) on L-type calcium current from rabbit ventricular myocytes. J Pharm Pharmacol, 53(12), 1671-8. Dofet. Dofet. Dofet.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pettignano, R, Chambliss, RC, Darsey, E, Heard, M, Michael, RN, & Reese, C. (1996). Cisapride-induced dysrhythmia in a pediatric patient receiving extracorporeal life support [Case Report]. Critical Care Med, 24 (7), 1268-71[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rampe, D, Murawsky, MK, Grau, J, & Lewis, EW. (1998). The antipsy-chotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther. 286(2), 788-93. Dofet. Dofet. Dofet.[Abstract/Free Full Text]
  • Rampe, D, Roy, M-L, Dennis, A, & Brown, AM. (1997). A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett, 417, 28-32. Cisa, Terf. Cisa, Terf. Cisa, Terf.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Redfern, WS, Carlsson, L, Davis, AS, Lynch, WG, MacKenzie, I, Palethorpe, S, Siegl, PKS, Strang, I, Sullivan, AT, Wallis, R, Camm, AJ, & Hammond, TG. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsades de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res, 58, 32-45. Cisa, Dofet, Terf, Verap. Cisa, Dofet, Terf, Verap. Cisa, Dofet, Terf, Verap.[Abstract/Free Full Text]
  • Rezazadeh, S, Hesketh, JC, & Fedida, D. (2004). Rb+ flux through hERG channels affects the potency of channel blocking drugs: Correlation with data obtained using a high-throughput Rb+ efflux assay. J Biomolec Screen, 9(7), 588-97
  • Ridley, JM, Dooley, PC, Milnes, JT, Witchel, HJ, & Hancox, JC. (2004). Lidoflazine is a high affinity blocker of the HERG K(+)channel. J Mol Cell Cardiol, 36(5), 701-5. Verap. Verap. Verap.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Roden, DM. (1998). Taking the "idio" out of "idiosyncratic": predicting Torsades de Pointes. PACE, 21, 1029-34[Medline] [Order article via Infotrieve]
  • Roden, DM. (2004). Drug therapy: drug-induced prolongation of the QT interval. N Engl J Med, 350(10), 1013-22[Free Full Text]
  • Rosen, MR, Ilvento, JP, Gelband, H, & Merker, C. (1974). Effects of verapamil on electrophysiologic properties of canine cardiac Purkinje fibers. J Pharmacol Exp Ther, 189(2), 414-22[Abstract/Free Full Text]
  • Roy, ML, Dumaine, R, & Brown, AM. (1996). HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation, 94, 817-23[Abstract/Free Full Text]
  • Sanguinetti, MC, & Jurkiewicz, NK. (1990). Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by Class III antiarrhythmic agents. J Gen Physiol, 96, 195-215[Abstract/Free Full Text]
  • Sanguinetti, MC, Jiang, C, Curran, ME, & Keating, MT. (1995). A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell, 81, 299-307[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Shah, RR, & Hondeghem, LM. (2005). Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm, 2(7), 758-72[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Smith, PL, Baukrowitz, T, & Yellen, G. (1996). The inward rectification mechanism of the HERG cardiac potassium channel. Nature, 379, 833-36[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Snyders, DJ, & Chaudhary, A. (1996). High affinity open channel block by dofetilide of hERG expressed in a human cell line. Mol Pharmacol, 49, 949-55. Dofet. Dofet. Dofet.[Abstract]
  • Spector, PS, Curran, ME, Zou, A, Keating, MT, & Sanguinetti, MC. (1996). Fast inactivation causes rectification of the IKr channel. J Gen Physiol, 107, 611-19
  • Su, Z, Martin, R, Cox, BF, & Gintant, G. (2004). Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+ channel. J Mol Cell Cardiol, 36(1), 151-60[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Tarantino, P, Appleton, N, & Lansdell, K. (2005). Effect of trazodone on hERG channel current and QT-interval. Eur J Pharmacol. 510(1–2), 75-85. Cisa. Cisa. Cisa.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Thomas, D, Kiehn, J, Katus, HA, & Karle, CA. (2003). Defective protein trafficking in hERG-associated hereditary long QT syndrome (LQT2): molecular mechanisms and restoration of intracellular protein processing. Cardiovasc Res, 60(2), 235-41[Abstract/Free Full Text]
  • Towbin, JA, & Vatta, M. (2001). Molecular biology and the prolonged QT syndromes. Am J Med, 110, 385-98[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Trudeau, MC, Warmke, JW, Ganetzky, B, & Robertson, GA. (1995). HERG, a human inward rectifier in the voltage-gated potassium channel family. Science, 269, 92-5[Abstract/Free Full Text]
  • Tsujimae, K, Suzuki, S, Yamada, M, & Kurachi, Y. (2004). Comparison of kinetic properties of quinidine and dofetilide block of HERG channels. Eur J Pharmacol, 493(1–3), 29-40[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Van Haarst, DA, van’t Klooster, GAE, van Gerven, JMA, Schoemaker, RC, van Oene, JC, Burggraaf, J, Coene, M-C, & Cohen, AF. (1998). The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther, 64, 542-6. Cisa. Cisa. Cisa.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wang, J, Della-Penna, K, Wang, H, Karczewski, J, Connolly, TM, Koblan, KS, Bennett, PB, & Salata, JJ. (2003). Functional and pharmacological properties of canine ERG potassium channels. Am J Physiology (Heart Circ Physiol), 284(1), H256-67. Cisa. Cisa. Cisa.
  • Weerapura, M, Hebert, TE, & Nattel, S. (2002). Dofetilide block involves interactions with open and inactivated states of HERG channels. Pflugers Arch, 443(4), 520-31[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Witchel, HJ, Milnes, JT, Mitcheson, JS, & Hancox, JC. (2002). Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes. J Pharmacol Toxicol Methods, 48(2), 65-80[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Witchel, HJ, Pabbathi, VK, Hofmann, G, Paul, AA, & Hancox, JC. (2002). Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and vetnricular L-type calcium currents. FEBS Lett, 512, 59-66. Fluox. Fluox. Fluox.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Witchel, HJ, Dempsey, CE, Sessions, RB, Perry, M, Milnes, JT, Hancox, JC, & Mitcheson, JS. (2004). The low-potency, voltage-dependent HERG blocker propafenone—molecular determinants and drug trapping. Mol Pharmacol, 66(5), 1201-12[Abstract/Free Full Text]
  • Woosley, RL, Chen, Y, Freiman, JP, & Gillis, RA. (1993). Mechanism of the cardiotoxic actions of terfenadine. JAMA, 269(12), 1532-6. Terf. Terf. Terf.[Abstract/Free Full Text]
  • Yan, GX, Wu, Y, Liu, T, Wang, J, Marinchak, RA, & Kowey, PR. (2001). Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome: direct evidence from intra-cellular recordings in the intact left ventricular wall. Circulation, 103(23), 2851-6[Abstract/Free Full Text]
  • Yang, T, Snyders, D, & Roden, DM. (2001). Drug block of I(kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol, 38(5), 737-44. Verap. Verap. Verap.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yao, J-A, Du, X, Lu, D, Baker, RL, Daharsh, E, & Atterson, P. (2005). Estimation of potency of hERG channel blockers: Impact of voltage protocol and temperature. J Pharmacol Toxicol Meth, 52, 146-53[CrossRef][Medline] [Order article via Infotrieve]
  • Zeltser, D, Justo, D, Halkin, A, Prokhorov, V, Heller, K, & Viskin, S. (2003). Torsade de Pointes due to noncardiac drugs: Most patients have easily identifiable risk factors. Medicine, 82(4), 282-90[CrossRef][Medline] [Order article via Infotrieve]
  • Zhang, S, Zhou, Z, Gong, Q, Makielski, JC, & January, CT. (1999). Mechanism of block and identification of the verapamil binding domain to HERG potassium Channels. Circ. Res, 84, 989-98. Verap. Verap. Verap.[Abstract/Free Full Text]
  • Zhou, Z, Gong, Q, Ye, B, Fan, Z, Makielski, JC, Robertson, GA, & January, CT. (1998). Properties of hERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J, 74, 230-41[Web of Science][Medline] [Order article via Infotrieve]

Toxicologic Pathology, Vol. 34, No. 1, 81-90 (2006)
DOI: 10.1080/01926230500431376
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Gintant, G. A.
Right arrow Articles by Cox, B. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gintant, G. A.
Right arrow Articles by Cox, B. F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?